Thomas Borody
#10,117
Most Influential Person Now
Australian gastroenterologist
Thomas Borody's AcademicInfluence.com Rankings
Thomas Borodymedical Degrees
Medical
#37
World Rank
#71
Historical Rank
Gastroenterology
#1
World Rank
#1
Historical Rank
Download Badge
Medical
Why Is Thomas Borody Influential?
(Suggest an Edit or Addition)According to Wikipedia, Thomas J. Borody is an Australian gastroenterologist. In the 1980s Borody contributed to development of a treatment for Helicobacter pylori. During the COVID-19 pandemic he became embroiled in controversy for advocating an ivermectin-based purported "cure" for COVID-19 without transparently declaring his financial interest in it.
Thomas Borody's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Treating Clostridium difficile infection with fecal microbiota transplantation. (2011) (873)
- Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study (2017) (808)
- Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial (2017) (807)
- Fecal microbiota transplantation and emerging applications (2012) (590)
- Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients (2014) (558)
- Therapeutic potential of fecal microbiota transplantation. (2013) (515)
- Treatment of Ulcerative Colitis Using Fecal Bacteriotherapy (2003) (409)
- Human interdigestive motility: variations in patterns from esophagus to colon. (1986) (382)
- Bacteriotherapy Using Fecal Flora: Toying With Human Motions (2004) (288)
- Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. (2019) (249)
- Rapid dissolution of gallstones by methyl tert-butyl ether. Preliminary observations. (1985) (249)
- Cure of duodenal ulcer after eradication of Helicobacter pylori (1990) (238)
- Durable Alteration of the Colonic Microbiota by the Administration of Donor Fecal Flora (2010) (232)
- Fecal Microbiota Transplantation: Indications, Methods, Evidence, and Future Directions (2013) (214)
- Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication (1989) (206)
- Bowel‐flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? (1989) (189)
- Fecal microbiota transplantation: techniques, applications, and issues. (2012) (159)
- Phagocyte‐specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease (2008) (157)
- The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals (2015) (156)
- Motility of the terminal ileum and ileocecal sphincter in healthy humans. (1984) (141)
- Cholelitholysis using methyl tertiary butyl ether. (1985) (130)
- Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. (1995) (115)
- Efficacy and safety of single‐triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study (2003) (108)
- Helicobacter pylori-negative duodenal ulcer. (1991) (104)
- Therapeutic faecal microbiota transplantation: current status and future developments (2013) (104)
- Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis (MS): 942 (2011) (98)
- Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. (1996) (94)
- Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection: A Multicenter Experience (2015) (90)
- Effects of morphine and atropine on motility and transit in the human ileum. (1985) (87)
- Helicobacter pylori reinfection rate, in patients with cured duodenal ulcer. (1994) (85)
- Efficacy and safety of rifabutin‐containing ‘rescue therapy’ for resistant Helicobacter pylori infection (2006) (85)
- Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis. (2020) (79)
- Endoscopic fecal microbiota transplantation: "first-line" treatment for severe clostridium difficile infection? (2011) (77)
- The Consensus from the Mycobacterium avium ssp. paratuberculosis (MAP) Conference 2017 (2017) (75)
- Reversal of Idiopathic Thrombocytopenic Purpura [ITP] with Fecal Microbiota Transplantation [FMT]: 941 (2011) (70)
- Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). (2020) (68)
- Motility of the Small Intestine after Proctocolectomy and Heal Pouch‐Anal Anastomosis (1985) (61)
- Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars. (2007) (59)
- Helicobacter pylori reinfection 4 years post-eradication (1992) (59)
- Helicobacter pylori-negative gastric ulcer (1992) (57)
- Sulfapyridine appearance in plasma after salicylazosulfapyridine (1986) (55)
- Fecal microbiota transplantation: current status and future directions (2011) (54)
- Smoking does not contribute to duodenal ulcer relapse after Helicobacter pylori eradication (1992) (53)
- Impaired host immunity contributes to Helicobacter pylori eradication failure (2002) (53)
- Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. (2021) (49)
- Chronic constipation reversed by restoration of bowel flora. A case and and a hypothesis (1992) (48)
- "Putting back the bugs": bacterial treatment relieves chronic constipation and symptoms of irritable bowel syndrome (1993) (47)
- Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice (2020) (45)
- Defined microbiota transplant restores Th17/RORγt+ regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas (2019) (44)
- Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy. (1992) (42)
- The GI microbiome and its role in Chronic Fatigue Syndrome: A summary of bacteriotherapy (2012) (42)
- Evaluation of whole blood antibody kit to detect active Helicobacter pylori infection. (1996) (41)
- Apparent reversal of early gastric mucosal atrophy after triple therapy for Helicobacter pylori. (1993) (41)
- Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead (2015) (39)
- Evolution of fecal microbiota transplantation in methodology and ethical issues. (2019) (39)
- In vitro dissolution of cholesterol gallstones. A study of factors influencing rate and a comparison of solvents. (1985) (38)
- Sulfapyridine appearance in plasma after salicylazosulfapyridine. Another simple measure of intestinal transit. (1986) (36)
- Use of high efficacy, lower dose triple therapy to reduce side effects of eradicating Helicobacter pylori. (1994) (36)
- “flora power”—fecal bacteria cure chronic C. difficile diarrhea (2000) (35)
- Gastroenterologist perceptions of faecal microbiota transplantation. (2015) (32)
- Primary treatment of Crohn’s disease: combined antibiotics taking center stage (2011) (29)
- Reversal of Inflammatory Bowel Disease (IBD) with Recurrent Faecal Microbiota Transplants (FMT): 979 (2011) (29)
- Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy. (2000) (29)
- Fecal microbiota transplantation as a new therapy: from Clostridioides difficile infection to inflammatory bowel disease, irritable bowel syndrome, and colon cancer. (2019) (28)
- Fecal Microbiota Transplantation in Ulcerative Colitis: Review of 24 Years Experience: 1644 (2012) (25)
- MAP-associated Crohn's disease MAP, Koch's postulates, causality and Crohn's disease. (2007) (25)
- Eradication of Helicobacter pylori may not reverse severe gastric dysplasia. (1995) (24)
- Probiotics under the regulatory microscope (2005) (23)
- Bacteriotherapy in Chronic Fatigue Syndrome (CFS): A Retrospective Review: 1481 (2012) (22)
- Mycobacterium avium ss paratuberculosis-associated Diseases: Piecing the Crohn’s Puzzle Together (2012) (21)
- Microbiota transplant therapy and autism: lessons for the clinic (2019) (21)
- M1209 Clostridium difficile Complicating Inflammatory Bowel Disease: Pre- and Post-Treatment Findings (2008) (21)
- Fecal microbiota transplantation: a new standard treatment option for Clostridium difficile infection (2013) (21)
- 600 Multi Donor Intense Faecal Microbiota Transplantation is an Effective Treatment for Resistant Ulcerative Colitis: A Randomised Placebo-Controlled Trial (2016) (21)
- Laparoscopic excision of a Brunner’s gland hamartoma of the duodenum (2002) (20)
- Selective Th2 pattern of cytokine secretion in Mycobacterium avium subsp. paratuberculosis infected Crohn's disease (2008) (20)
- 998 Long-Term Follow-up Study of Fecal Microbiota Transplantation (FMT) for Severe or Complicated Clostridium difficile Infection (CDI) (2013) (20)
- Profound remission in Crohn’s disease requiring no further treatment for 3–23 years: a case series (2020) (18)
- Targeted Combination Antibiotic Therapy Induces Remission in Treatment-Naïve Crohn’s Disease: A Case Series (2020) (18)
- Lost microbes of COVID-19: Bifidobacterium, Faecalibacterium depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity (2022) (18)
- Drivers and determinants of strain dynamics following fecal microbiota transplantation (2021) (17)
- Detection of SARS-CoV-2 from patient fecal samples by whole genome sequencing (2020) (16)
- Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients (2021) (15)
- Myoclonus‐dystonia Affected by GI Microbiota?: 940 (2011) (15)
- Long-Term Bacterial and Fungal Dynamics following Oral Lyophilized Fecal Microbiota Transplantation in Clostridioides difficile Infection (2021) (14)
- 'Global warming' to Mycobacterium avium subspecies paratuberculosis. (2014) (14)
- Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn's disease (2015) (13)
- Putting Crohn’s on the MAP: Five Common Questions on the Contribution of Mycobacterium avium subspecies paratuberculosis to the Pathophysiology of Crohn’s Disease (2020) (13)
- Flora Power"-- fecal bacteria cure chronic C. difficile diarrhea. (2000) (13)
- Oxygenating mouthguard alleviates hypoxia during gastroscopy. (1992) (13)
- Treatment of Severe Constipation Improves Parkinsonʼs Disease (PD) Symptoms: 999 (2009) (13)
- Safety of Fecal Microbiota Transplantation (FMT) in Immunocompromised (Ic) Patients with Inflammatory Bowel Disease (IBD): Presidential Poster: 1840 (2013) (12)
- Fecal microbiota transplantation in gastrointestinal diseases: what practicing physicians should know. (2015) (11)
- Could fecal microbiota transplantation cure all Clostridium difficile infections? (2014) (11)
- Is Crohn's disease ready for fecal microbiota transplantation? (2014) (10)
- Fecal microbiota transplantation for ulcerative colitis-where to from here? (2019) (10)
- Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections—Exploratory study (2021) (10)
- Faecal Microbiota Transplantation is Effective for the Initial Treatment of Clostridium difficile Infection: A Retrospective Clinical Review (2020) (10)
- Selective reduction of anti‐Helicobacter pylori IgG subclass antibody in gastric carcinoma (2005) (10)
- Faecal microbiota transplantation alleviates symptoms of depression in individuals with irritable bowel syndrome: A case series (2020) (9)
- Treatment of patients with failed eradication — a personal view (1996) (9)
- Lactoferrin: milking ulcers? (2003) (9)
- Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond (2015) (9)
- CHLORBUTOL TOXICITY AND DEPENDENCE (1979) (9)
- Eradication therapies for Helicobacter pylori. (1998) (9)
- Anti-Mycobacterial Antibiotic Therapy Induces Remission in Active Paediatric Crohn’s Disease (2020) (8)
- Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy (2020) (7)
- Therapeutic Potential of the Human Gastrointestinal Microbiome (2013) (7)
- Helicobacter pylori eradication failure--'salvage' therapies needed. (1998) (7)
- Evaluation of anti‐Helicobacter pylori IgG2 antibody for the diagnosis of Helicobacter pylori infection in western and Chinese populations (2005) (7)
- S131 CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results From a Randomized, Placebo-Controlled Trial (2021) (6)
- The many faces of Crohn's Disease: Latest concepts in etiology (2012) (6)
- Metagenomic Hi-C of a Healthy Human Fecal Microbiome Transplant Donor (2020) (6)
- Complication rates of ablation therapies for hepatocellular carcinoma: a difficult comparison with an easy solution. (2006) (5)
- High prevalence of Crohn disease and ulcerative colitis among older people in Sydney (2021) (5)
- Crohn’s strictures open with anti-mycobacterial antibiotic therapy: A retrospective review (2020) (5)
- Fecal microbiota transplantation: A 'How-To' guide for nurses. (2015) (5)
- 152 A Long-Term Follow-Up Study of the Efficacy and Safety of Fecal Microbiota Transplant (FMT) for Recurrent/Severe/Complicated C. difficile Infection (CDI) in the Elderly (2014) (5)
- Microbial determinants of effective donors in faecal microbiota transplantation for UC (2022) (5)
- Treatment of severe Crohn's disease (CD)-using rifabutin-macrolide-clofazimine combination: Results at 30–37 months (2000) (5)
- Can the response to eradication therapy in Helicobacter pylori infection be predicted? (2003) (5)
- Obstacles to Donor Recruitment for Faecal Microbiota Transplantation: Experiences From the FOCUS Study: 650 (2014) (5)
- Probiotics and the Colon (2003) (5)
- Tu2022 Twelve Week Storage Trial of Microbial Viability in Lyophilized and Frozen Fecal Microbiota Preparations (2015) (4)
- Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 diseases (2022) (4)
- RELEASE OF MOTILIN BY METOCLOPRAMIDE (1980) (4)
- Re: W. de Boer: Gastric outlet obstruction and Helicobacter pylori. (1997) (4)
- Towards monotherapy for Helicobacter pylori infection: First results with a single triple capsule (1998) (4)
- Strain population structure varies widely across bacterial species and predicts strain colonization in unrelated individuals (2020) (4)
- Fecal Microbiota Transplantation (FMT) for Treatment of Clostridium difficile Infection (CDI) in Immunocompromised Patients: ACG Governors Award for Excellence in Clinical Research: 611 (2013) (3)
- Dietary Intakes of Recipients of Faecal Microbiota Transplantation: An Observational Pilot Study (2021) (3)
- How effective are quadruple therapies as first-line H. pylori eradication therapies? (2005) (3)
- A Comparative Clinical Study of a Novel Pre-colonoscopy Bowel Capsule Preparation Against Two Commercially Available Liquid Preparations (2021) (3)
- Prolonged Endoscopic Remission With Mucosal Healing in Crohnʼs Patients: Treatment Cessation for 3-23 Years: 754 (2017) (3)
- Fecal Microbiota Transplantation Decreases Amyloid Load and Improves Cognition in Alzheimer’s (2019) (3)
- Dietary Management for Faecal Microbiota Transplant: An International Survey of Clinical and Research Practice, Knowledge and Attitudes (2021) (3)
- Quadruple should be first-line therapy for Helicobacter pylori infection (2000) (3)
- Treatment of First-Time Clostridium difficile Infection With Fecal Microbiota Transplantation: 1354 (2015) (3)
- Severe recurrent Crohn's disease of ileocolonic anastomosis and antimicrobial (anti-mycobacterial) therapy. (2006) (3)
- Improved Eradication Protocol for Blastocystis Hominis: 1363 (2015) (2)
- S145 Week 24 Efficacy and Safety Data from PRISM3: A Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection (2021) (2)
- Treatment-Naïve Ulcerative Colitis Patient Treated With Lyophilized Full Spectrum Microbiota: A Case Study: 1983 (2017) (2)
- Diagnostic Value of Fundic Red Spots in Helicobacter pylori (Hp) Infection: 139 (2012) (2)
- Antibiotic Therapy for Treatment-Naive Crohnʼs Disease Patients: 594 (2016) (2)
- Use of Lyophilised Microbiota Capsules for Fecal Microbiota Transplantation in Patients With Clostridium difficile Infection (2018) (2)
- M1060 Rapid and Superior Diagnosis of H. pylori Infection By 14C-Urea HeliprobeTM Test Versus the PYtest® (2008) (2)
- IDDF2018-ABS-0034 High age-specific prevalence of inflammatory bowel disease amongst the elderly in the city of canada bay area, sydney: a metropolitan, population-based study (2018) (2)
- Rescue H. pylori Therapy in the Clinical Setting: 1486 (2012) (2)
- Skewered diverticulum: another cause of abdominal pain (2001) (2)
- Successful Bacterial Engraftment Identified by Next-Generation Sequencing Predicts Success of Fecal Microbiota Transplant for Clostridioides difficile (2021) (2)
- Fecal Microbiota Transplantation (2019) (2)
- T1030 Colchicine Plus Olsalazine for Treatment of Constipation-Predominant Irritable Bowel Syndrome (2009) (2)
- Encapsulated Lyophilized Fecal Microbiota Therapy for the Treatment of Clostridium difficile Infection: 943 (2016) (1)
- Resistant Fistulizing Crohns Disease Treated with Combination of Infliximab, Anti-MAP and Hyperbaric Oxygen (HBO): 1655 (2012) (1)
- Oral fecal microbiota transplant for recurrent Clostridium difficile in pediatric autoimmune enteropathy. (2019) (1)
- S3437 Antibiotic Therapy Followed by Faecal Microbiota Transplantation Alleviates Epilepsy – A Case Report (2020) (1)
- 680 LYOPHILIZED ORALLY ADMINISTERED FECAL MICROBIOTA TRANSPLANTATION IN THE MANAGEMENT OF ULCERATIVE COLITIS (LOTUS STUDY) – RESULTS FROM THE INDUCTION PHASE OF A RANDOMIZED CONTROLLED TRIAL (2021) (1)
- OP019 In faecal microbiota transplantation (FMT) for ulcerative colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short-chain fatty acid production are associated with remission (FOCUS study) (2018) (1)
- The Role of Fecal Microbiota Transplantation in Neurological Diseases (2019) (1)
- Sa1913 CONSENSUS GUIDELINES FOR THE REGULATION, PRODUCTION AND USE OF FECAL MICROBIOTA TRANSPLANTATION IN CLINICAL PRACTICE (2020) (1)
- Demonstration of Intracellular Mycobacterium Species in Crohnʼs Disease Using Novel Technologies: 1990 (2015) (1)
- Anti-Protozoal Enema Treatment for Blastocystis hominis and Dientamoeba fragilis: Does Volume Matter? (2018) (1)
- Anti-Mycobacterium avium SS Paratuberculosis (MAP) Therapy and Fistula Closure in Patients with Severe Crohnʼs Disease: 1124 (2006) (1)
- Laparoscopic vagotomy for chronic duodenal ulcer. (1992) (1)
- Fecal Microbiota Transplantation Reduces Pathology and Improves Cognition in a Mouse Model of Alzheimer’s Disease (2022) (1)
- Improvement in Food Intolerance Symptoms after Pretreatment with Antibiotics Followed by Faecal Microbiota Transplantation: A Case Report (2021) (1)
- Entamoeba histolytica: Another Cause of Crohnʼs Disease: 990 (2009) (1)
- Sa1149 Superior Diagnosis of H. pylori Infection With 14C-Urea HelicapTM Capsules Versus Standard Pytest® Capsules (2013) (1)
- Gut microbiota bacterial strain richness is species specific and limits therapeutic engraftment (2022) (1)
- Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study (2017) (1)
- T1258 Phagocyte-Specific S100 Proteins Are Activators of Pattern Recognition Receptors and Released During Active Inflammatory Bowel Disease (2008) (1)
- Targeting the microbiome in Crohn’s disease (2022) (1)
- Adverse Effects of Liquid vs. Encapsulated Lyophilized Fullspectrum Microbiota for the Treatment of Clostridium Difficile Infection (2017) (1)
- Fecal microbiota transplantation for Clostridium difficile infection: A surgeon׳s perspective (2014) (1)
- S144 CP101 Engraftment Drives Efficacy: Results From a Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for Prevention of Recurrent C. difficile Infection (2021) (1)
- S551 Loss of Bifidobacteria in Lyme Disease: Cause or Effect (2022) (0)
- S232 Clinical Remission in Collagenous Colitis Following Antibiotic Treatment in Seven Patients (2021) (0)
- Years Continuous Anti-MAP Therapy for Crohnʼs -Observation of Side Effects: 1163 (2008) (0)
- S1914 Antibiotics Followed by an Ultra Filtrate Fecal Microbiota Transplantation Improves Symptoms of Autism in an Adult Male (2021) (0)
- Improved method of Helicobacter pylori eradication. (1999) (0)
- The exocrine pancreas (1987) (0)
- The Extra Pharmacopoeia / Martindale (2017) (0)
- Su1744 Lyophilized Fecal Microbiota Transplantation and Cryoprotectants for Viable Bacteria Preservation (2016) (0)
- S146 Evaluation of Engraftment and Diversity Following Open-Label Administration of CP101, an Investigational Oral Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection, in the PRISM-EXT Trial (2022) (0)
- Mo1929 ORALLY ADMINISTERED LYOPHILIZED FECAL MICROBIOTA TRANSPLANTATION IN CLOSTRIDIOIDES DIFFICILE INFECTION - LONG TERM CLINICAL AND MICROBIOLOGICAL OUTCOMES (2020) (0)
- S3353 Improvement in Paediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections (PANDAS) Syndrome Following Treatment With a Combination of Antibiotics and Fecal Microbiome Transplantation (FMT) (2022) (0)
- Methods of treating a bacterial infection using a fixed-dose pharmaceutical composition comprising three antibiotics (2018) (0)
- S3352 Gut Microbiome 6 Months After Fecal Microbiota Transplant (FMT) in an Adolescent With Autism Using Familial Donor (2022) (0)
- Irish society of Gastroenterology joint meeting with midland gastroenterology society (1985) (0)
- Transfer Therapy alters gut ecosystem and improves and autism symptoms: an open-label study. (2017) (0)
- Colonoscopic Diagnostic Features of Stool and Mucosa of Inflamed versus Healed Ulcerative Colitis After Repeated Fecal Microbiota Transplantation: 2721 (2017) (0)
- S0538 A Low-Residue Diet in Combination With a Novel Encapsulated Bowel Preparation Formula Leads to Improved Outcomes in Patients Who Cannot Tolerate Conventional Bowel Preparations (2020) (0)
- Lyophilised Full Spectrum Microbiota Capsules for Treatment of Severe Clostridium difficile Infection in 2 Patients in ICU: A Case Study (2018) (0)
- Letter in reply: more power to ivermectin multidrug therapy. (2022) (0)
- Detection and Comparison of Mycobacterium avium paratuberculosis by Culture and PCR in Peripheral Blood of Crohnʼs Patients and Normal Controls: 2720 (2017) (0)
- Anti-MAP Therapy for Pediatric Crohnʼs Disease: 1713 (2013) (0)
- Probiotics and the Colon Therapeutic and Prophylactic Uses (2003) (0)
- Su2019 ADJUNCTIVE SUPPLEMENTATION WITH AN ORAL HEME IRON POLYPEPTIDE MAY DELAY THE NEED FOR SUBSEQUENT INTRAVENOUS IRON INFUSIONS IN PATIENTS AT RISK OF RECURRENT IRON DEFICIENCY (2020) (0)
- L actoferrin : milking ulcers ? * (2003) (0)
- Faecal Microbiota Transplantation as Primary Treatment for Clostridioidoes difficile Infection-evidence for Change (2021) (0)
- S1010 Importance of Bifidobacteria in Crohn’s Disease (2022) (0)
- Tu1036: LONG TERM CLINICAL OUTCOMES AFTER FECAL MICROBIOTA TRANSPLANTATION - AN INTERIM ANALYSIS (2022) (0)
- S227 Messenger RNA SARS-CoV-2 Vaccines Affect the Gut Microbiome (2022) (0)
- Mo1628 – Prospective Pre-Colonoscopy Bowel Preparation Study Comparing Novel Capsule Bowel Preparation (CBP) Vs High Volume Polyethylene Glycol Electrolyte Solution Vs Low Volume Polyethylene Glycol Electrolyte Solution (2019) (0)
- OP30 Lyophilised orally administered faecal microbiota transplantation for Active Ulcerative Colitis (LOTUS study) (2021) (0)
- Compositions for treatment of chlamydial associates diseases (1999) (0)
- Mo1391: PROLONGED REPEATED FECAL MICROBIOTA TRANSPLANTATION IMPROVES SYMPTOMS AND QUALITY OF LIFE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME (2022) (0)
- Pre-Antibiotic Treatment Followed by Prolonged Repeated Faecal Microbiota Transplantation Improves Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome: An Observational Australian Clinical Experience (2022) (0)
- SUPPLEMENTAL OXYGEN THERAPY DURING ENDOSCOPY AND RECOVERY. RESPONSE (1993) (0)
- Response to article “A retrospective outcome study of 42 patients with chronic fatigue syndrome, 30 of whom has irritable bowel syndrome. Half were treated with oral approaches, and half were treated with faecal microbiome transplantation” (2019) (0)
- W1222 Anti-MAP Rescues Anti-TNF Failures for Over 4 Years (2009) (0)
- Myasthenia gravis in Melanesians in the Solomon islands. (1981) (0)
- DEVELOPMENT OF NOVEL THERAPIES FOR GUT DYSBIOSES A Thesis Submitted For the Degree Of Doctor of Science By (2016) (0)
- Compositions and methods for treating primary sclerosing cholangitis and related disorders (2017) (0)
- The Efficacy of Liquid Fecal Microbiota Transplantation in the Treatment of Symptoms Associated With Post-Infectious Irritable Bowel Syndrome: A Retrospective Analysis: 427 (2017) (0)
- Two-day enema antibiotic therapy for parasite eradication and resolution of symptoms (2020) (0)
- S2099 Persistent Damage to the Gut Microbiome Following Messenger RNA SARS-CoV-2 Vaccine (2022) (0)
- Response to Drs. Famularo et al. (2001) (0)
- Profound Remission in Inflammatory Bowel Disease Following Antibiotics Then Fecal Microbiota Transplantation: A Retrospective Study (2018) (0)
- Changes in Crohnʼs Disease Activity Index and C-reactive Protein Levels During Anti-MAP Therapy: 1293 (2009) (0)
- S2458 Rosacea Improved Following Treatment With Combination Antibiotics and Fecal Microbiota Transplantation: Two Case Reports (2022) (0)
- 2930 Does Triple Antibiotic Therapy Reduce Faecal Calprotectin Levels and Gastrointestinal Symptoms in Patients With Ulcerative Colitis? A Retrospective Study (2019) (0)
- L milking ulcers (2003) (0)
- S3151 Personalised Combination Antibiotic Therapy Is Effective for Constipation (2020) (0)
- Development of novel therapies for gut dysbioses (2016) (0)
- Methods of oxygen delivery during upper gastrointestinal endoscopy. (1994) (0)
- S1913 Antibiotic Combination Therapy Improves Symptoms of Parkinson’s Disease in Individuals With Chronic Constipation (2021) (0)
- Compositions and methods for treating diverticulitis and related disorders (2018) (0)
- 843 Crohn’s Strictures Open With Anti-Mycobacterial Antibiotic Therapy (AMAT): A Retrospective Review (2019) (0)
- Acknowledgment of 2010 Reviewers (2011) (0)
- Longitudinal Scarring in Severe Colonic Crohnʼs Disease Treated with Anti-Mycobacterium avium SS Paratuberculosis (MAP) Therapy: 1125 (2006) (0)
- P160 MUCOSAL RELEASE OF PHAGOCYTE-SPECIFIC S100 PROTEINS IS STRONGLY ENHANCED DURING ACTIVE INFLAMMATORY BOWEL DISEASE (2007) (0)
- Nasal Vs Oro-Nasal Oxygenation and Capnography During Endoscopy (2008) (0)
- Tu1509: PROFOUND REMISSION FOUND IN TEN ULCERATIVE COLITIS PATIENTS USING INTENSIVE COLONIC LAVAGE FOLLOWED BY FAECAL MICROBIOTA TRANSPLANTATION - CASE SERIES (2022) (0)
- FMT; How Do Alternate Formats Compare?: 1004 (2016) (0)
- Patient with Severe Constipation-Predominant Irritable Bowel Syndrome Successfully Treated With Encapsulated Lyophilized Full Spectrum Microbiota: A Case Study: 2890 (2017) (0)
- Intra-colonic Infusion of Anti-parasite Agents for Resitant Blastocystis hominis: Long-term Follow-up: 421 (2011) (0)
- Comparison Eradication Protocol for Dientamoeba fragilis: 1359 (2015) (0)
- Sa1904 EFFICACY OF ANTI-PARASITIC TREATMENT FOR BLASTOCYSTIS HOMINIS AND DIENTAMOEBA FRAGILIS BY COLONIC INFUSION IN PATIENTS WHO FAILED PRIOR TREATMENTS: A MEDICAL RECORD REVIEW (2020) (0)
- S2474 Ankylosing Spondylitis Improved Following Faecal Microbiota Transplantation: Two Case Reports (2022) (0)
This paper list is powered by the following services:
Other Resources About Thomas Borody
What Schools Are Affiliated With Thomas Borody?
Thomas Borody is affiliated with the following schools:
